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Antioxidants in the Intensive Care Unit
To the Editor:
The Critical Care Perspective review of the use of antioxidants in the
intensive care unit (ICU) by Jain and Chandel in the December 1,
2013, issue of the Journal (1) presented a possible mechanism for
the lack of a positive outcome in most clinical trials using these
agents. However, understanding possible approaches for the
prevention of acute oxidant stress in the ICU requires taking the
kinetics of the various redox-related reactions into consideration.
In essence, effectiveness of an antioxidant requires it to out-
compete the interaction of the oxidant with tissue components, for
it is the latter interaction that results in tissue injury. It is not
Table 1: Subject Characteristics
Healthy Asthma
Induced sputum study
n 11 35
Age, yr 37 6 12 36 6 13
Female, n (%) 5 (45) 23 (66)
BMI, kg/m2 26.6 6 4.9 28.7 6 7.1
FEV1, L 4.01 6 1.00 2.73 6 0.90
FEV1, % predicted 108.1 6 11.0 79.1 6 17.4
PC20 (n = 31) N/A 0.69 (0.12–12.60)
On ICS, n (%) N/A 19 (54)
Smoking history
Never, n (%) 8 (73) 17 (49)
Former, n (%) 3 (27) 18 (51)
Pack-years 0 (0–1.36) 0 (0–10.00)
Acute asthma study
n 11
Age, yr 43 6 11
Female, n (%) 8 (73)
On ICS, n (%) 9 (82)
On LABA, n (%) 6 (55)
On anticholinergic, n (%) 3 (27)
% admitted 2 (18)
Smoking history
Never, n (%) 3 (27)
Former, n (%) 7 (64)
Current, n (%) 1 (9)
Pack-years 1 (0–8)
On ICS, n (%) 3 (60)
Mucin study
n 5
Age, yr 39.4 6 14.5
Female, n (%) 3 (60)
BMI, kg/m2 29.7 6 7.4
FEV1, L 2.55 6 0.86
FEV1, % predicted 73.6 6 17.4
Smoking history
Never, n (%) 3 (60)
Former, n (%) 2 (40)
Pack-years 0 (0–8.5)
PC20 0.39 (0.15–1.19)
On ICS, n (%) 3 (60)
Definition of abbreviations: BMI = body mass index; ICS = inhaled
corticosteroids; LABA = long-acting b-agonists; PC20 = provocative
concentration of methacholine (mg/ml) that results in a 20% fall in FEV1.
Values are presented as mean 6 SD or median (range), unless otherwise
noted.
CORRESPONDENCE
Correspondence 1007
known precisely which of the reactive oxygen species (ROS) are
responsible for the bulk of tissue injury, and that may vary
depending on the inciting agent and other circumstances. One
important reaction may be the interaction of ferrous iron (Fe21)
with H2O2 to generate hydroxyl radical (
dOH) (Fenton reaction).
Both the generation of dOH by this reaction and its subsequent
interaction with tissue components are essentially instantaneous,
and there is no conceivable way for a potential scavenger
compound to out-compete those reactions. Superoxide dismutase
will not prevent tissue oxidation under these conditions, but rather,
if the rate of superoxide production is rate limiting, will increase
the H2O2 flux that is the source of
dOH radicals. ROS generated
by other reactions may be more susceptible to the action of
antioxidants, but only at the expense of some tissue damage. As
such, it is understandable, as concluded by Jain and Chandel, that
antioxidants may not be effective in the treatment of acute lung
injury associated with oxidant stress (1). However, there may be
some hope; that is, preventing the generation of ROS could be
an effective strategy to prevent lung injury. Jain and Chandel
indicated that a major source of ROS with acute lung injury is
through activation of one or more of the reduced nicotinamide
adenine dinucleotide (NADPH) oxidases (1). There has recently
been considerable research activity related to the development of
nontoxic inhibitors of NADPH oxidases (2, 3), including one from
our laboratory based on inhibiting the activation pathway for
NADPH oxidase type 2 (4–6). It seems likely that potential
therapeutic agents based on inhibition of this group of enzymes will
be developed for use in the ICU in the near future. Thus, it is
premature to abandon hope for preventing oxidant-induced lung
injury in the intensive care setting. n
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From the Authors:
We thank Drs. Fisher and Forman for their thoughtful description
of the detrimental effects of high levels of reactive oxygen
species (ROS), which we agree are likely to contribute to tissue
injury during disease through Fenton chemistry and other
reactions. In our perspective (1), we highlight the recent
paradigm shift in oxidant biology, which recognizes that low
levels of ROS serve as signaling molecules that play key roles in
the biologic adaptation to environmental stress and pathogen
challenge. We suggest that the unrecognized interruption of
these pathways might explain why the current arsenal of
nonselective antioxidants, including N-acetylcysteine, vitamin C,
and vitamin E, have failed in clinical trials in the intensive care
unit and in other disease models, and we suggest that trials of
these and other nonselective antioxidants should no longer be
pursued. We agree that selectively targeted antioxidants—for
example, those designed to specifically target the NADPH
oxidase or mitochondrial ROS generation—continue to hold
promise; however, we suggest that their use must be coupled with
a clear understanding of their normal biologic function. For
example, NADPH oxidases play an important role in pathogen
clearance, vascular reactivity, and lung repair. Whether the
cost of inhibiting these normal, oxidant-dependent signaling
pathways is justified by the benefit of preventing oxidant-
mediated tissue injury is not immediately clear. n
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Classification of the Idiopathic
Interstitial Pneumonias
To the Editor:
The recently revised American Thoracic Society/European
Respiratory Society classification of the idiopathic interstitial
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